Immunoglobulin allotypes influence antibody responses to mucin 1 in patients with gastric cancer

Cancer Research

Volumn 68, Issue 11, 2008, Pages 4442-4446

  Pandey, Janardan P ^a   Nietert, Paul J ^b   Von Mensdorff Pouilly, Silvia ^c   Klaamas, Kersti ^d   Kurtenkov, Oleg ^d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN ALLOTYPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MUCIN 1; CA 15-3 ANTIGEN; MUC1 PROTEIN, HUMAN;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CANCER PATIENT; CAUCASIAN; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENETIC MARKER; HEAVY CHAIN; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; STOMACH CARCINOMA; ANTIBODY PRODUCTION; IMMUNOLOGY; MIDDLE AGED; STOMACH TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODY FORMATION; CA-15-3 ANTIGEN; FEMALE; HUMANS; IMMUNOGLOBULIN ALLOTYPES; MALE; MIDDLE AGED; STOMACH NEOPLASMS;

EID: 49249083347     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5607     Document Type: Article

References (36)

1. Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004;82:249-93.
2. Coronella-Wood JA, Hersh EM. Naturally occurring Bcell responses to breast cancer. Cancer Immunol Immunother 2003;52:715-38.
3. Silk AW, Finn OJ. Cancer vaccines: a promising cancer therapy against all odds. Future Oncol 2007;3:299-306.
4. Kurtenkov O, Klaamas K, Mensdorff-Pouilly S, Miljukhina L, Shljapnikova L, Chuzmarov V. Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival. Acta Oncol 2007;46:316-23.
5. Cramer DW, Titus-Ernstoff L, McKolanis JR, et al. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1125-31.
6. Lieberman R, Stiffel C, Asofsky R, Mouton D, Biozzi G, Benacerraf B. Genetic factors controlling anti-sheep erythrocyte antibody response and immunoglobulin synthesis in backcross and F2 progeny of mice genetically selected for "high" or "low" antibody synthesis. J Exp Med 1972;136:790-8.
7. Pandey JP. Immunoglobulin GM and KM allotypes and vaccine immunity. Vaccine 2001;19:613-7.
8. Hoffman RW, Sharp GC, Irvin WS, Anderson SK, Hewett JE, Pandey JP. Association of immunoglobulin Km and Gm allotypes with specific antinuclear antibodies and disease susceptibility among connective tissue disease patients. Arthritis Rheum 1991;34:453-8.
9. Kameda H, Pandey JP, Kaburaki J, Inoko H, Kuwana M. Immunoglobulin allotype gene polymorphisms in systemic sclerosis: interactive effect of MHC class II and Km genes on anticentromere antibody production. Ann Rheum Dis 1998;57:366-70.
10. Pandey JP, Page GP, Silver RM, LeRoy EC, Bona CA. Anti-fibrillin-1 autoantibodies in systemic sclerosis are Gm and Km allotype restricted. Exp Clin Immunogenet 2001;18:123-9.
11. Pertovaara M, Hurme M, Antonen J, Pasternack A, Pandey JP. Immunoglobulin KM and GM gene polymorphisms modify the clinical presentation of primary Sjögren's syndrome. J Rheumatol 2004;31:2175-80.
12. Pandey JP, Shannon BT, Tsang KY, Fudenberg HH, Camblin JG. Heterozygosity at Gm loci associated with humoral immunity to osteosarcoma. J Exp Med 1982;155:1228-32.
13. vonMensdorff-Pouilly S, Gourevitch MM, Kenemans P, et al. An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumour Biol 1998;19:186-95.
14. Vyas GN, Fudenberg HH, Pretty HM, Gold ER. A new rapid method for genetic typing of human immunoglobulins. J Immunol 1968;100:274-9.
15. Schanfield MS, van LoghemE. Human immunoglobulin allotypes. In: Weir DM, editor. Handbook of experimental immunology. Boston: Blackwell;19 86. p. 94.1-18.
16. Steinberg AG, Cook CE. The distribution of human immunoglobulin allotypes. New York: Oxford University Press;198 1. p. 250.
17. Grubb R. Advances in human immunoglobulin allotypes. Exp Clin Immunogenet 1995;12:191-7.
18. Pandey JP. Genetics of immunoglobulins. In: Virella G, editor. Medical immunology. New York: Marcel Dekker, Inc.;2007. p. 73-81.
19. Shows TB, McAlpine PJ, Boucheix C, et al. Guidelines for human gene nomenclature. An international system for human gene nomenclature (ISGN, 1987). Cytogenet Cell Genet 1987;46:11-28.
20. Martin W, Goodnow CC. Burst-enhancing role of the IgG membrane tail as a molecular determinant of memory. Nat Immunol 2002;3:182-8.
21. Wakabayashi C, Adachi T, Wienands J, Tsubata T. A distinct signaling pathway used by the IgG-containing B cell antigen receptor. Science 2002;298:2392-5.
22. Cooper LJN, Robertson D, Granzow R, Greenspan SN. Variable domain-identical antibodies exhibit IgG subclass-related differences in affinity and kinetic constants as determined by surface plasmon resonance. Mol Immunol 1994;31:577-84.
23. McLean GR, Torres M, Elguezabal N, Nakouzi A, Casadevall A. Isotype can affect the fine specificity of an antibody for a polysaccharide antigen. J Immunol 2002;169:1379-86.
24. Morahan G, Berek C, Miller JFAP. An idiotypic determinant formed by both immunoglobulin constant and variable regions. Nature 1983;301:720-2.
25. H1 constant region domain modulate antigen binding affinity of antibodies? J Clin Invest 1996;98:2235-43.
26. Torres M, Fernandez-Fuentes N, Fiser A, Casadevall A. The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen. J Biol Chem 2007;282:13917-27.
27. Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, et al. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer 2001;93:97-106.
28. Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. Curr Opin Immunol 2007;19:239-45.
29. Stockmeyer B, Valerius T, Repp R, et al. Preclinical studies with FcγR bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res 1997;57:696-701.
30. Pandey JP. Genetic polymorphism of Fc. Science 2006;311:1376-7.
31. Moreno M, Bontkes HJ, Scheper RJ, et al. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Lett 2007;257:47-55.
32. Czerwinski M, Siemaszko D, Siegel DL, Spitalnik SL. Only selected light chains combine with a given heavy chain to confer specificity for a model glycopeptide antigen. J Immunol 1998;160:4406-17.
33. Primi D, Drapier AM, Cazenave PA. Highly preferential VH-VL pairing in normal B cells results in antigen-independent selection of the available repertoire. J Immunol 1987;138:1607-12.
34. Biggar RJ, Pandey JP, Henle W, Nkrumah FK, Levine PH. Humoral immune response to Epstein-Barr virus antigens and immunoglobulin allotypes in African Burkitt lymphoma patients. Int J Cancer 1984;33:577-80.
35. Li D, Li H, Zhang P, et al. Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity. Eur J Immunol 2006;36:1324-36.
36. Pandey JP, Prohászka Z, Veres A, Füst G, Hurme M. Epistatic effects of genes encoding immunoglobulin GM allotypes and interleukin-6 on the production of autoantibodies to 60- and 65-kDa heat-shock proteins. Genes Immun 2004;5:68-71.